Global Reach Trasis serves radiopharmacy teams across 65+ countries, presenting a large potential customer base including nuclear medicine departments, research centers, radiopharmaceutical production facilities, and pharmaceutical companies that may require scalable automated synthesis systems, dose preparation equipment, and regulatory support.

End-to-End Offering Opportunity to upsell and cross-sell across the full workflow from automated synthesis to shielding solutions and consumables, complemented by development services, GMP API production, and regulatory support to accelerate clinic and market timelines.

Growth Signals Recognition as Trends Gazelles indicates high growth potential and market credibility; combine this with a mid-size workforce and modest revenue range to target mid-market radiopharmacy facilities and expanding departments seeking scalable, compliant solutions.

Tech Enablement Leverage Trasis’ digital and collaborative tools (DocuSign, Continuous Delivery, analytical tracking via Google Analytics, CAD design) to streamline procurement, deployment, and regulatory documentation; present as capabilities to accelerate customer validation and regulatory readiness.

Financial Profile Current revenue in the low-to-mid multi-million range with 201-500 employees suggests opportunities for long-term contracts, service agreements, and consumables replenishment, including potential for expansion into GMP API production and longer-term maintenance partnerships.